SG11202003893UA - Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy - Google Patents
Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapyInfo
- Publication number
- SG11202003893UA SG11202003893UA SG11202003893UA SG11202003893UA SG11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA
- Authority
- SG
- Singapore
- Prior art keywords
- monospecific
- cancer therapy
- immune checkpoint
- bispecific proteins
- checkpoint regulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762611543P | 2017-12-29 | 2017-12-29 | |
PCT/US2018/067868 WO2019133817A1 (en) | 2017-12-29 | 2018-12-28 | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003893UA true SG11202003893UA (en) | 2020-05-28 |
Family
ID=67068142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003893UA SG11202003893UA (en) | 2017-12-29 | 2018-12-28 | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
Country Status (13)
Country | Link |
---|---|
US (2) | US11643470B2 (zh) |
EP (2) | EP4268848A3 (zh) |
JP (2) | JP7362614B2 (zh) |
KR (1) | KR102452246B1 (zh) |
CN (2) | CN111344019B (zh) |
AU (1) | AU2018394939B2 (zh) |
BR (1) | BR112020013133A2 (zh) |
CA (1) | CA3082036A1 (zh) |
ES (1) | ES2966569T3 (zh) |
MY (1) | MY195411A (zh) |
SG (1) | SG11202003893UA (zh) |
TW (2) | TW202116811A (zh) |
WO (1) | WO2019133817A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102469248B1 (ko) * | 2018-02-28 | 2022-11-22 | 에이피 바이오사이언시스, 아이엔씨. | 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질 |
WO2021073611A1 (zh) * | 2019-10-17 | 2021-04-22 | 江苏康宁杰瑞生物制药有限公司 | Ox40/pd-l1双特异性抗体 |
WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
CN112830972A (zh) * | 2019-11-25 | 2021-05-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
TW202334203A (zh) * | 2021-11-19 | 2023-09-01 | 德商皮里斯製藥有限公司 | 新穎的ox40及pd-l1特異性融合蛋白 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541297A (en) | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
BRPI0613361A2 (pt) * | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
CN103221427B (zh) | 2010-08-23 | 2016-08-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
WO2013181634A2 (en) * | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
PE20211291A1 (es) * | 2014-03-31 | 2021-07-20 | Genentech Inc | Anticuerpos anti-ox40 y metodos de uso |
SG11201608106PA (en) * | 2014-03-31 | 2016-10-28 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
WO2016081384A1 (en) * | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
KR20170108946A (ko) * | 2014-12-05 | 2017-09-27 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 |
US20180147271A1 (en) | 2015-05-18 | 2018-05-31 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
WO2017068181A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain ox40-receptor agonist proteins |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
BR112018011336A2 (pt) * | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
WO2017123673A2 (en) | 2016-01-11 | 2017-07-20 | Inhibrx Lp | Multivalent and multispecific ox40-binding fusion proteins |
US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
KR102469248B1 (ko) | 2018-02-28 | 2022-11-22 | 에이피 바이오사이언시스, 아이엔씨. | 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질 |
WO2019184909A1 (zh) * | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
-
2018
- 2018-12-28 AU AU2018394939A patent/AU2018394939B2/en active Active
- 2018-12-28 EP EP23187547.7A patent/EP4268848A3/en active Pending
- 2018-12-28 CN CN201880072318.7A patent/CN111344019B/zh active Active
- 2018-12-28 EP EP18897074.3A patent/EP3731875B1/en active Active
- 2018-12-28 CN CN202410242154.5A patent/CN118047873A/zh active Pending
- 2018-12-28 MY MYPI2020003383A patent/MY195411A/en unknown
- 2018-12-28 JP JP2020533119A patent/JP7362614B2/ja active Active
- 2018-12-28 SG SG11202003893UA patent/SG11202003893UA/en unknown
- 2018-12-28 BR BR112020013133-4A patent/BR112020013133A2/pt unknown
- 2018-12-28 WO PCT/US2018/067868 patent/WO2019133817A1/en unknown
- 2018-12-28 ES ES18897074T patent/ES2966569T3/es active Active
- 2018-12-28 TW TW109134512A patent/TW202116811A/zh unknown
- 2018-12-28 KR KR1020207012822A patent/KR102452246B1/ko active IP Right Grant
- 2018-12-28 CA CA3082036A patent/CA3082036A1/en active Pending
- 2018-12-28 TW TW107147877A patent/TWI742336B/zh active
-
2020
- 2020-05-11 US US16/871,799 patent/US11643470B2/en active Active
-
2022
- 2022-04-14 JP JP2022067239A patent/JP2022109934A/ja active Pending
-
2023
- 2023-03-09 US US18/181,339 patent/US20230322939A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN118047873A (zh) | 2024-05-17 |
CA3082036A1 (en) | 2019-07-04 |
KR102452246B1 (ko) | 2022-10-12 |
EP3731875A4 (en) | 2021-12-08 |
EP3731875B1 (en) | 2023-10-04 |
NZ763957A (en) | 2023-10-27 |
CN111344019B (zh) | 2024-03-15 |
TWI742336B (zh) | 2021-10-11 |
JP2022109934A (ja) | 2022-07-28 |
US11643470B2 (en) | 2023-05-09 |
JP2021509258A (ja) | 2021-03-25 |
MY195411A (en) | 2023-01-19 |
TW202116811A (zh) | 2021-05-01 |
ES2966569T3 (es) | 2024-04-23 |
CN111344019A (zh) | 2020-06-26 |
KR20200061397A (ko) | 2020-06-02 |
US20230322939A1 (en) | 2023-10-12 |
RU2020120518A (ru) | 2022-01-31 |
EP4268848A3 (en) | 2024-01-10 |
BR112020013133A2 (pt) | 2020-12-08 |
TW201932486A (zh) | 2019-08-16 |
AU2018394939A1 (en) | 2020-05-14 |
AU2018394939B2 (en) | 2022-02-24 |
EP4268848A2 (en) | 2023-11-01 |
RU2020120518A3 (zh) | 2022-01-31 |
JP7362614B2 (ja) | 2023-10-17 |
US20200270357A1 (en) | 2020-08-27 |
EP3731875A1 (en) | 2020-11-04 |
WO2019133817A1 (en) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290496A (en) | Therapeutic antibodies and their uses | |
HK1257730A1 (zh) | 抗despr單克隆抗體用於癌症和中風的靶向療法及成像 | |
HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
EP3377102C0 (en) | ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES | |
SG11202003893UA (en) | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy | |
IL248511A0 (en) | Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3 | |
IL276303A (en) | Methods of treating cancer with ANTI-PD-1 antibodies | |
HK1247091A1 (zh) | 治療抗體及其用途 | |
IL256000A (en) | Quantifying her 2 protein for optimal cancer therapy | |
IL278862A (en) | Monospecific and multispecific anti-TMEFF2 antibodies and uses thereof | |
IL289247A (en) | Bispecific molecules block an immune checkpoint | |
HUE053128T2 (hu) | Bispecifikus antitestek rák immunterápiában történõ alkalmazásra | |
SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
IL273092A (en) | HDAC suppressor in combination with immune checkpoint modulators for cancer treatment |